Articles published by KalVista Pharmaceuticals, Inc.
![](https://mms.businesswire.com/media/20230214005142/en/670569/5/Kalvista-Logo-Final-01.jpg)
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20230210005087/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
February 10, 2023
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20230207005607/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20230203005139/en/670569/5/Kalvista-Logo-Final-01.jpg)
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20230202005270/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20230105005157/en/670569/5/Kalvista-Logo-Final-01.jpg)
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20230104005237/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20221227005065/en/670569/5/Kalvista-Logo-Final-01.jpg)
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20221208005259/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
December 08, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20221205005236/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20221114005441/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20221107005455/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 07, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20221102005290/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20221031005246/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20221019005249/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20221017005179/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
October 17, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20221007005538/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
October 07, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20221005005298/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20221004005432/en/940761/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20220930005137/en/670569/5/Kalvista-Logo-Final-01.jpg)
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20220908005213/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
September 08, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20220902005066/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20220823005348/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20220802005394/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20220719005532/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20220707005180/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 07, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20220705005688/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2022
Via Business Wire
Tickers
KALV
![](https://mms.businesswire.com/media/20220705005314/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20220623005458/en/670569/5/Kalvista-Logo-Final-01.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.